**STUDY PURPOSE**

The purpose of this preclinical study was to evaluate the antitumor activity of a combination therapy consisting of bintrafusp alfa plus a VEGF pathway inhibitor in mouse syngeneic tumor models.

**METHODS**

The combination therapy of bintrafusp alfa plus anti-VEGF or VEGF receptor tyrosine kinase inhibitors (VEGF-TKIs) was tested in the following syngeneic mouse tumor models:

- CT26 subcutaneous colon carcinoma
- 4T1 orthotopic mammary carcinoma
- 4T1-luciferase orthotopic renal carcinoma
- Renca orthotopic renal carcinoma

**RESULTS**

Table 1. TCGA gene expression correlation analysis of TGFβ, TGFBR2 and RTKs in breast cancer and CRC

<table>
<thead>
<tr>
<th>Gene</th>
<th>Correlation Coefficient (R)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGFβ</td>
<td>&gt; 0.7</td>
</tr>
<tr>
<td>TGFBR2</td>
<td>0.6-0.69</td>
</tr>
<tr>
<td>RTKs</td>
<td>0.4-0.49</td>
</tr>
</tbody>
</table>

**STUDY CONCLUSION**

Our findings support the investigation of a combination therapy consisting of bintrafusp alfa plus anti-VEGF or RTK inhibitors for the treatment of solid tumors.

**REFERENCES**

1. Lan 2018, PMID: 28345322
2. Ferrari 2009, PMID: 19182561
3. Nishio 2019, PMID: 30222731
4. Jiang 2017, PMID: 28455791

**ACKNOWLEDGMENTS**

This study was funded by Merck KGaA, Darmstadt, Germany, and is performed in reliance between Merck KGaA and Quintessa.

*Corresponding author: Tsz-Lun Yeung, tsz-lun.yeung@emdserono.com*